1. Home
  2. ADCT vs CZNC Comparison

ADCT vs CZNC Comparison

Compare ADCT & CZNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADCT
  • CZNC
  • Stock Information
  • Founded
  • ADCT 2011
  • CZNC 1864
  • Country
  • ADCT Switzerland
  • CZNC United States
  • Employees
  • ADCT N/A
  • CZNC N/A
  • Industry
  • ADCT Biotechnology: Pharmaceutical Preparations
  • CZNC Major Banks
  • Sector
  • ADCT Health Care
  • CZNC Finance
  • Exchange
  • ADCT Nasdaq
  • CZNC Nasdaq
  • Market Cap
  • ADCT 241.0M
  • CZNC 286.0M
  • IPO Year
  • ADCT 2020
  • CZNC N/A
  • Fundamental
  • Price
  • ADCT $2.97
  • CZNC $18.49
  • Analyst Decision
  • ADCT Strong Buy
  • CZNC
  • Analyst Count
  • ADCT 5
  • CZNC 0
  • Target Price
  • ADCT $7.75
  • CZNC N/A
  • AVG Volume (30 Days)
  • ADCT 694.8K
  • CZNC 26.6K
  • Earning Date
  • ADCT 05-14-2025
  • CZNC 04-23-2025
  • Dividend Yield
  • ADCT N/A
  • CZNC 6.01%
  • EPS Growth
  • ADCT N/A
  • CZNC 15.34
  • EPS
  • ADCT N/A
  • CZNC 1.75
  • Revenue
  • ADCT $75,817,000.00
  • CZNC $108,114,000.00
  • Revenue This Year
  • ADCT $9.19
  • CZNC $6.78
  • Revenue Next Year
  • ADCT $16.27
  • CZNC $4.59
  • P/E Ratio
  • ADCT N/A
  • CZNC $10.61
  • Revenue Growth
  • ADCT 10.49
  • CZNC 5.33
  • 52 Week Low
  • ADCT $1.05
  • CZNC $16.50
  • 52 Week High
  • ADCT $4.13
  • CZNC $22.68
  • Technical
  • Relative Strength Index (RSI)
  • ADCT 75.65
  • CZNC 42.28
  • Support Level
  • ADCT $1.83
  • CZNC $18.65
  • Resistance Level
  • ADCT $2.35
  • CZNC $19.06
  • Average True Range (ATR)
  • ADCT 0.31
  • CZNC 0.39
  • MACD
  • ADCT 0.12
  • CZNC -0.06
  • Stochastic Oscillator
  • ADCT 93.03
  • CZNC 17.13

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

About CZNC Citizens & Northern Corp

Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.

Share on Social Networks: